The CaSR protein and its ligands
The extracellular calcium-sensing receptor (CaSR) is a family C GPCR that plays a pivotal role in maintaining extracellular calcium (Ca 2+ o) homeostasis. [Drug/molecular target nomenclature throughout this manuscript conforms to BJP's Concise Guide to PHARMACOLOGY (Alexander et al., 2013) ]. It is composed of 1078 amino acids in four main domains beyond the signal peptide (http://www.casrdb.mcgill.ca). These are an N-terminal extracellular Venus FlyTrap (VFT) domain (residues 22-528) linked via a cysteine-rich domain (residues 529-612) to the heptahelical signalling domain (residues 613-862) and a C-terminal intracellular domain (residues o can also activate the CaSR via the heptahelical or extracellular loop domains, as evidenced by its activity at 'headless' CaSR constructs that lack the N-terminal domain of the receptor (Ray and Northup, 2002; Mun et al., 2004; Ray et al., 2005 and Pb 2+ (McGehee et al., 1997; Handlogten et al., 2000) . The VFT is additionally the site of action of endogenous allosteric agonists, including cationic polyamines, such as spermine and spermidine (Quinn et al., 1997) , and endogenous allosteric modulators, including L-amino acids and glutathione analogues (for a review, see Conigrave and Hampson, 2010) . Aminoglycoside antibiotics, such as neomycin, gentamicin and tobramycin, also activate the CaSR Ward et al., 2002) , although their binding site is yet to be identified. Synthetic allosteric modulators that bind in the heptahelical domain and extracellular loops of the CaSR have also been identified, which include calcimimetics, such as cinacalcet (and related phenylalkylamines) (Nemeth et al., 1998) , and calcilytics, such as NPS 2143 (Nemeth, 2002) .
Biased signalling from the CaSR
The CaSR couples to Gq/11, Gi/o and G12/13 (Huang et al., 2004; Davey et al., 2012) and even Gs in some cell contexts (Mamillapalli and Wysolmerski, 2010) . Stimulation of distinct effectors downstream of these G proteins mediates cellular responses to CaSR activation (Figures 1-3 ). Its promiscuous binding to numerous endogenous ligands, and its propensity to couple to multiple G proteins and downstream signalling pathways, make the CaSR an ideal candidate for biased signalling (also known as stimulus bias, liganddirected trafficking of receptor stimulus, functional selectivity or biased agonism). Biased signalling arises from the ability of different ligands to favour distinct conformational receptor states, each possessing its own coupling preferences to downstream signalling pathways (Kenakin, 2011) .
Biased signalling operates in response to various endogenous CaSR agonists and modulators. In HEK293 cells, for instance, when stimulated with Ca 2+ o, the CaSR preferentially couples to inhibition of cAMP production and stimulation of inositol 1,4,5-trisphosphate (IP3) accumulation over phosphorylation of ERK 1 and 2 (ERK1/2) (Thomsen et al., 2012a) . Spermine, however, strongly favours ERK1/2 phosphorylation (Thomsen et al., 2012a) . Similarly, although both Ca ), whereas L-Phe mediates lower frequency oscillations (up to 2 min −1 ) (Rey et al., 2010 Davies et al., 2007) . In contrast, activation of the CaSR by L-Phe is reported to promote its interaction with G12/13, Rho, filamin-A and transient receptor potential cation (TRPC) 1 channels, resulting in TRPC1 channel opening and Ca 2+ influx from the extracellular fluid (Rey et al., 2005; (Rey et al., 2005) . These results suggest that the cellular location of CaSR expression and its subsequent exposure to a subset of ligands that are present in specific compartments (e.g. in the luminal compartments of the gastrointestinal tract or renal tubules) may govern its signalling, enabling selective activation of intracellular signalling pathways depending on which ligand binds the receptor.
This review will summarize our current understanding of the physiological roles of the human CaSR, the implications of biased signalling arising from the CaSR and how biased signalling may be engendered to manipulate CaSR function in pathological states.
The CaSR's roles in calcium homeostasis
Two well-characterized actions of the CaSR in response to a rise in systemic Ca 
Figure 1
CaSR-mediated regulation of PTH and calcitonin release. Suppression of PTH release from parathyroid chief cells is dependent on CaSR activation of Gq/11-mediated pathways and possibly the suppression of cAMP synthesis (not shown). CaSR activation of PI-PLC and phosphorylation of ERK1/2 leads to changes in the immediate secretion of PTH. CaSR activity has additionally been linked to changes in PTH gene transcription and subsequent PTH synthesis. Calcitonin release from parafollicular C-cells of the thyroid gland has been linked to Gq/11-mediated stimulation of PI-PLC, PC-PLC and the opening of L-type Ca 2+ channels but calcitonin release is independent of ERK1/2 signalling and inhibition of cAMP. PIP2, phospholipid phosphatidylinositol 4,5-bisphosphate.
expressed by parathyroid chief cells and renal cortical thick ascending limb cells of Henle's loop. Indeed, in response to hypercalcaemia, the CaSR mediates enhanced renal calcium excretion, independent of changes in PTH levels (Kantham et al., 2009; Loupy et al., 2012) . This effect requires CaSRmediated inhibition of Ca 2+ re-absorption via both paracellular and transcellular pathways (Figure 2 ) (for a review, see Riccardi and Brown, 2010) . Together, these effects rapidly stimulate renal calcium excretion and lower the serum calcium level. In addition, the CaSR appears to mediate three further responses to elevated Ca 2+ o: (i) suppression of 1,25(OH)2D3 synthesis, which lowers the drive for intestinal Ca 2+ absorption; (ii) negative modulation of PTH-induced phosphate excretion to raise the serum inorganic phosphate level; and (iii) decreased osteoclastic-dependent bone resorption. CaSR-dependent suppression of bone resorption is mediated via receptors on osteoblasts, which suppress osteoclastogenesis, via receptors on thyroid C-cells, which promote the release of calcitonin, and via receptors on osteoclasts themselves, which suppress resorptive activity (for a review, see Riccardi and Kemp, 2012) . The concerted effect of these various CaSR-mediated responses is a pronounced decrease in ionized Ca 2+ o concentration and a more modest increase in serum phosphate level.
The CaSR also facilitates the transport of Ca 2+ across the placenta in support of fetal skeletal development and growth (Kovacs et al., 1998) and promotes Ca 2+ transport into milk during lactation via its expression in mammary duct epithelial cells (Cheng et al., 1998; VanHouten, 2005) . Recently, selective knockout of the CaSR in the lactating mouse mammary gland confirmed that the mammary gland receptor promotes calcium transport into milk and, in turn, calcium accrual in suckling neonates (Mamillapalli et al., 2013) . Furthermore, CaSR-null lactating dams from this model exhibited hypercalcaemia and appropriately suppressed serum PTH levels, demonstrating that the mammary gland CaSR has a physiological role in maintaining normal maternal serum calcium levels during lactation (Mamillapalli et al., 2013) .
Roles of the CaSR in bone and cartilage cells
The CaSR has been implicated in bone mineralization and linear bone growth. In osteoblasts, the CaSR modulates the expression of genes that promote bone mineralization and osteoblast differentiation. Activation of the CaSR in osteoblasts by Sr 2+ , for instance, stimulates phosphoinositide 3-kinase (PI 3-kinase) and consequent Akt phosphorylation (Rybchyn et al., 2011) . CaSR activation also promotes Wntdependent β-catenin translocation to the nucleus and attendant osteoblast differentiation (Rybchyn et al., 2011) . The CaSR promotes the differentiation of cartilage-producing chrondrocytes in the growth plate, leading to the growth of the long bones during skeletal development .
The CaSR in cells of the osteoblast-osteocyte lineage also suppresses osteoclastogenesis by inducing down-regulation of receptor activator of NFκB ligand (TNFSF11) and up-regulation of its decoy receptor osteoprotegerin (Brennan et al., 2009; Saidak and Marie, 2012) . Reduced expression of TNFSF11 results in reduced osteoclast number, reduced osteoclast activity and reduced bone resorption (Dvorak-Ewell et al., 2011) . In addition, CaSRs expressed on osteoclasts appear to mediate high Ca 2+ o-induced apoptosis (Kanatani et al., 1999; Mentaverri et al., 2006) , which is dependent on PLC, IP3, nuclear translocation of NF-κB and enhanced caspase activity (Mentaverri et al., 2006) .
Some of the effects of elevated Ca 2+ o in bone are mediated not only by the CaSR but also by other family C GPCRs, including GPRC6, which mediates some of the responses to Ca 2+ o in osteoblasts and thereby contributes to the control of bone mineralization (Pi et al., 2010) .
Roles of the CaSR in tissues that are not involved in calcium homeostasis
Perhaps surprisingly, the CaSR is also expressed in tissues that are not involved in Ca o-induced suppression of transepithelial Ca 2+ transport is dependent on PLA2-mediated inhibition of renal outer medullary potassium (ROMK) channels (Wang et al., 1997; Huang et al., 2007; Cha et al., 2011) , which contributes to enhanced urinary excretion of Na + , Ca 2+ and Mg
2+
. In addition, Ca 2+ o suppresses transcellular Na + and Cl − re-absorption secondary to Gi/omediated inhibition of PTH-and vasopressin-stimulated cAMP production (de Jesus Ferreira et al., 1998 ; for review, see Gamba and Friedman, 2009 re-absorption, the CaSR has recently been reported to up-regulate the expression of claudin-14, a key inhibitor of a claudin-16/19-dependent divalent cation selective paracellular pathway in the thick ascending limb (Gong et al., 2012) .
example, CaSR expression in the heart and blood vessels has been linked to the modulation of BP (see Smajilovic et al., 2011 for a review) and protection against vascular calcification (Alam et al., 2009) , raising the possibility that a drug that selectively modulates CaSR function in this setting might be effective at lowering BP and/or reducing or even reversing calcification.
In the CNS, the CaSR is widely expressed in neurons and glial cells and is subject to developmental regulation (Rogers et al., 1997) . For example, it promotes neuronal differentiation, myelination and growth during development (Ferry et al., 2000; Chattopadhyay et al., 2008; Vizard et al., 2008) , and modulates neurotransmission in post-natal life (Phillips et al., 2008) .
In addition, the CaSR acts as an ionic strength sensor in the subfornical organ linked to the control of BP and whole body salt and water metabolism (Washburn et al., 1999) . It also directly modulates salt and water transport in the colon (Geibel and Hebert, 2009 ) and renal tubules (for a review, see Riccardi and Brown, 2010) .
CaSR expression has also been demonstrated in monocytes and macrophages (Yamaguchi et al., 1998; Olszak et al., 2000) , in which, alongside GPRC6, it activates the key inflammatory mediator NLRP3 (Lee et al., 2012; Rossol et al., 2012) , and in keratinocytes it acts as a mediator of differentiation . Consistent with this latter idea, keratinocyte-specific CaSR null mice demonstrate disordered skin development (Bikle et al., 2012; Tu et al., 2012) .
Modulation of macronutrient digestion, absorption, nutrient disposition and storage
The CaSR has multiple roles in the gastrointestinal tract dependent primarily on its expression by enteroendocrine cells as well as epithelial cells such as gastric parietal cells (for a review, see Conigrave and Brown, 2006) . Thus, CaSRs expressed by enteroendocrine G-cells detect nutrient L-amino acids (Geibel and Hebert, 2009 ) to stimulate the release of gastrin and thus gastric acid secretion (Feng et al., 2010) , and CaSRs expressed by I-cells mediate cholecystokinin (CCK) release (Liou et al., 2011; Wang et al., 2011) to support the digestion and absorption of macronutrients. In addition, CaSRs expressed by K-and L-cells mediate amino acidinduced release of gastric inhibitory peptide and glucagonlike peptide 1 (GLP-1), respectively (Mace et al., 2012) , to provide a mechanism by which gut luminal contents facilitate nutrient-dependent insulin release.
Consistent with its effects on gut hormone release and gastric acid secretion, CaSRs expressed in hepatocytes promote bile flow (Canaff et al., 2001) to facilitate digestion and absorption of fats and CaSRs expressed on adipocytes, in turn, facilitate fat storage by promoting adipocyte differentiation and adipogenesis (Cifuentes and Rojas, 2008; He et al., 2011; Reyes et al., 2012) . CaSR activation in adipose tissue also elevates the production of cytokines and chemokines, including IL-6, IL-1β, TNF-α and CC chemokine i mobilization assays (y axis) and ERK1/2 phosphorylation assays (x axis). If the receptor shows no preference for either pathway, points on the bias plots are coincident and the plots overlap with the line of identity (grey line). If it favours one of the pathways, the points fall away from this line towards the preferred pathway. Thus, naturally occurring mutations can engender stimulus bias.
2 and pro-inflammatory cytokines increase CaSR expression in adipocytes (Cifuentes et al., 2010) , suggesting the existence of a positive feedback loop. CaSR-mediated release of GLP-1 and the appetite reducing peptide, peptide YY (Mace et al., 2012) , as well as CCK provide satiety signals to the hypothalamus for the suppression of further feeding. Collectively, these findings suggest that the CaSR plays a fundamental role in the regulation of appetite and nutrient disposal.
Finally, the CaSR has been detected in pancreatic islet beta-cells, with evidence suggesting it modulates insulin release (Squires et al., 2000; Leech and Habener, 2003; Gray et al., 2006; Parkash and Asotra, 2011) .
Modulation of colonic epithelial cell differentiation and proliferation
The human colonic epithelium is composed of tubular invaginations known as 'crypts', at the base of which, stem cells proliferate rapidly and rise progressively towards the luminal surface. At the crypt base, CaSR expression is barely detectable, but it increases substantially as epithelial cells move towards the crypt apex promoting differentiation and suppressing proliferation (for a review, see Peterlik et al., 2013) dependent, in part, on Ca 2+ i mobilization and ERK1/2 activation (Bhagavathula et al., 2005; Rey et al., 2010) . Evidence that dietary calcium protects against colon cancer in human populations (for a review, see Peterlik et al., 2013) and that CaSR expression is markedly down-regulated in colon cancer (Kallay et al., 2003; Chakrabarty et al., 2005; Hizaki et al., 2011; Singh et al., 2012) has led to the hypothesis that the CaSR acts as a colonic tumour suppressor (for reviews, see Brennan et al., 2012; Singh et al., 2013) . Consistent with this idea, CaSR activators promote Wnt5a secretion to suppress inappropriate canonical Wnt signalling in colon cancer cells (MacLeod et al., 2007) .
Broader implications of the CaSR as a drug target
Given that the CaSR mediates diverse sensing and signalling functions and associated cellular responses in a surprising diversity of tissues and physiological contexts, it may be a suitable target for the treatment of disorders in which appropriate up-or down-regulated expression or increased or decreased receptor function could be engendered in a tissue and/or signal pathway selective manner.
Impact of CaSR mutations and polymorphisms in disorders of calcium metabolism and other disorders
The broad nature of the CaSR's physiological roles is highlighted by the effects of many naturally occurring mutations or single nucleotide polymorphisms (SNPs) that occur in the CaSR gene. These include, as might be expected, disorders of calcium homeostasis, including familial hypocalciuric hypercalcaemia and neonatal severe hyperparathyroidism, both of which arise from inactivating mutations, as well as autosomal dominant hypocalcaemia, which arises from activating mutations (Brown and MacLeod, 2001 ). In addition, more severe activating mutations of the CaSR induce the salt-wasting disorder Bartter syndrome type V (Watanabe et al., 2002) . These disorders result from mutation-specific impairments in receptor function, which include deficiencies in signalling capacity, trafficking to the cell surface and/or dimerization (Pidasheva et al., 2006; Grant et al., 2012; Leach et al., 2012) .
Other disorders that have been linked to CaSR mutations and/or SNPs include some forms of nephrolithiasis (Vezzoli et al., 2012) , idiopathic epilepsy (Kapoor et al., 2008) , Alzheimer's disease (Conley et al., 2009) , chronic pancreatitis (Muddana et al., 2008) , coronary heart disease and myocardial infarction (Marz et al., 2007) , prostate cancer (Shui et al., 2013) and rectal cancer (Speer et al., 2002) .
The majority of mutations that cause loss or gain in CaSR function and/or expression encode amino acid substitutions affecting the receptor's 19 residue signal peptide, its N-terminus, heptahelical domains and C-terminal tail (http://www.casrdb.mcgill.ca). Frameshift mutations (e.g. Ma et al., 2008) or nonsense mutations that introduce premature stop codons and thereby truncate the receptor protein (e.g. Rodrigues et al., 2011; Ward et al., 2013) also induce loss of function and/or expression. Receptor truncation can also arise from mutations in acceptor splice sites (D'Souza-Li et al., 2001) or from the insertion of Alu elements (Janicic et al., 1995) . The incidence of mutations in untranslated regions of the CaSR gene and their significance for disorders of calcium homeostasis are currently unknown.
Mutations that result in amino acid substitutions in the CaSR protein cause a range of functional outcomes, most commonly altering the signalling capacity of the receptor and/or reducing receptor expression. In fact, many 'loss-offunction' CaSR mutations cause reductions in cell surface expression, which limit signalling output in response to ligands (Leach et al., 2012) . As noted earlier, a reduction in CaSR expression has also been reported in the context of colonic tumourigenesis (Hizaki et al., 2011; Singh et al., 2012) and is a prominent feature of primary (Kifor et al., 1996; Cetani et al., 2000) and secondary (Kifor et al., 1996; Gogusev et al., 1997; Chikatsu et al., 2000; Yano et al., 2000) hyperparathyroidism. In these disease states, reduced CaSR expression is correlated with increased cell proliferation and decreased differentiation. Intriguingly, in rats treated with streptozotocin, which induces type I diabetes by destroying pancreatic islet beta-cells, CaSR expression was reduced in cardiomyocytes (Bai et al., 2012) , and up-regulated in the pancreas, liver and kidney (Haligur et al., 2012) . Thus, aberrant CaSR expression is a hallmark of various proliferative and metabolic disorders.
Engendering biased signalling at the CaSR
Given that endogenous ligands promote biased signalling at the CaSR, it is possible that synthetic drugs that bias CaSR signalling towards a particular 'signature' cluster of pathways to the exclusion of others will provide unique treatment opportunities for specific CaSR-mediated disorders. Likely design characteristics will be discussed in the following sections.
At present, strontium ranelate and cinacalcet are the only drugs in clinical practice that target the CaSR. Strontium ions are presumed to bind, like Ca 2+ o, in the VFT domain, thereby stimulating receptor signalling in osteoblasts and osteoclasts. In osteoblasts, Sr 2+ stimulates the expression of genes that promote cell proliferation and differentiation and downregulates expression of the pro-osteoclastogenic signal TNFSF11 (RANKL) and up-regulates expression of its decoy receptor osteoprotegerin (Brennan et al., 2009 ; for a review, see Saidak and Marie, 2012) . The outcome is reduced bone resorption together with enhanced bone formation. These effects appear to be primary contributors to the therapeutic efficacy of strontium ranelate in osteoporosis.
Cinacalcet, in contrast, binds in the receptor's heptahelical domain and acts as a positive allosteric modulator. Therapeutically, cinacalcet enhances Ca 2+ o-mediated receptor activation, which results in normalization of PTH levels in hyperparathyroidism via enhanced inhibition of PTH secretion from the parathyroid glands. Cinacalcet has also been used successfully to correct serum Ca o set point in the parathyroid to normal levels (Timmers et al., 2006; Reh et al., 2011; Wilhelm-Bals et al., 2012) . Furthermore, we and others have shown that phenylalkylamine calcimimetics such as cinacalcet are efficient pharmacochaperones that promote trafficking of loss-ofexpression CaSR mutants to the cell surface (White et al., 2009; Leach et al., 2013) , indicating that allosteric modulators could be used to regulate CaSR expression levels in diseases where its expression is attenuated. However, cinacalcet and other early generation phenylalkylamines frequently cause hypocalcaemia (Chonchol et al., 2009 ). Thus, its use is currently limited to patients with hyperparathyroidism in the context of end-stage kidney disease, parathyroid cancer or patients with moderate-severe primary hyperparathyroidism who cannot undergo parathyroidectomy. Cinacalcet causes a transient increase in the serum calcitonin level in both haemodialysis patients and in patients that have undergone renal transplantation (Serra et al., 2008; Arenas et al., 2013) . Following cinacalcet administration, the serum calcitonin level peaks after 2-3 h and normalizes after 6-12 h and may thus exacerbate the hypocalcaemic effect of calcimimetics. Calcitonin inhibits bone resorption (Hosking et al., 1981) and has traditionally been thought to decrease renal Ca 2+ re-absorption (Haas et al., 1971) , thus lowering the serum Ca 2+ o concentration. Although recent work suggests that calcitonin may, in fact, stimulate renal Ca 2+ re-absorption (Hsu et al., 2010) , suggesting calcitonin acts to redirect Ca 2+ from urine to bone rather than directly lowering serum Ca 2+ through enhanced secretion. Drugs that bias CaSR activity towards signalling pathways, which selectively suppress PTH secretion to the exclusion of others that promote calcitonin release, may reduce the incidence of symptomatic hypocalcaemic episodes. Proximal signalling events that link CaSR to the inhibition of PTH release and activation of calcitonin release have been identified (Figure 1 ) and will be described later.
Desired properties of CaSR modulators that selectively target PTH release
PTH secretion is promoted by GPCR-mediated stimulation of AC (for a review, see Brown and MacLeod, 2001) . Elevated Ca 2+ o suppresses the release of PTH from prepackaged vesicles and enhances PTH degradation in parathyroid cells (Habener et al., 1975) , and these effects are likely mediated by the CaSR. Activation of the CaSR by elevated Ca 2+ o suppresses AC activity and subsequent intracellular cAMP levels, for example, in dopamine-stimulated bovine parathyroid cells (Chen et al., 1989) . However, although overnight exposure to pertussis toxin attenuates CaSR-mediated suppression of cAMP levels demonstrating a role for Gi/o in the mechanism, Gi/o is not required for Ca o-dependent suppression of PTH secretion (Brown et al., 1992 ; for a review, see Brown and MacLeod, 2001) , pointing to the existence of key roles for other G-proteins in PTH secretion control. Consistent with this, mice, in which Gαq was selectively deleted in parathyroid cells on a global Gα11 null background, exhibited a phenotype that closely resembled that described for CaSR exon-5 null mice (Ho et al., 1995) , including growth retardation, parathyroid gland hyperplasia, hyperparathyroidism and severe hypercalcaemia (Wettschureck et al., 2007) . The first CaSR knockout strategy described employed a deletion of 20 bps in exon 5, which encodes residues 460-536 in the N-terminal extracellular domain, rendering the succeeding sequence out of frame (Ho et al., 1995) . It is now known that an exon 5-less CaSR splice variant is expressed and functional in several tissues including keratinocytes (Oda et al., 1998) and fetal lung (Finney et al., 2011) . More recently, tissuespecific deletion of CaSR exon 7 has revealed more severe phenotypes including developmental disturbances of cartilage and bone . CaSR-mediated suppression of PTH release via Gq/11 has been linked to activation of phosphatidylinositol-specific PLC (PI-PLC) resulting in the release of IP3 and DAG with consequent elevation of Ca 2+ i and activation of PKC (Corbetta et al., 2002) . PKC stimulates ERK1/2 phosphorylation and inhibition of either PKC or ERK1/2 signalling abolished the inhibitory effect of Ca 2+ o on PTH release (Corbetta et al., 2002) . PKC additionally activates PLD and PLA2 . CaSR-mediated PI 3-kinase activity also appears to contribute to the inhibitory control of PTH secretion (Corbetta et al., 2002) . Although it seems paradoxical that CaSR-mediated activation of pathways that lead to increased Ca 2+ i should suppress PTH secretion rather than activate it, as observed for other hormones that are released via exocytosis (Gustavsson et al., 2012) , it is possible that Gq/11 contributes to CaSR-mediated suppression of intracellular cAMP levels via Ca 2+ i-inihibited isoforms of AC (5, 6 or 9) as described for CaSR-expressing HEK-293 cells (Gerbino et al., 2005) and renin-secreting renal juxtaglomerular cells (Atchison and Beierwaltes, 2013) .
Both Gi/o and Gq/11 have been implicated in the control of gene expression that modulates PTH production (Thiel et al., 2012; Avlani et al., 2013 ) and release of Ca 2+ i has been linked to changes in PTH gene transcription (Ritter et al., 2008) .
CaSR-mediated release of calcitonin from thyroid parafollicular C-cells has also been linked to PLC-dependent signalling and appears to occur independently of the activation of ERK1/2 signalling and suppression of cAMP synthesis (Thomsen et al., 2012b) . However, the signalling mechanisms that couple CaSR activation to calcitonin release appear to be different in various cell models pointing to the need for a more robust human C-cell model. Thus, in sheep C-cells in primary culture, the CaSR was reported to signal via a pathway dependent on Gβγ-mediated stimulation of PI 3-kinase followed by the activation of PKCζ and PLC (McGehee et al., 1997; Liu et al., 2003) . However, in cultured rat 6-23 medullary thyroid carcinoma cells, PI 3-kinase was not required for Ca 2+ o-stimulated calcitonin secretion. Instead, it was driven by phosphatidylcholine-specific PLC (PC-PLC) as well as PI-PLC-dependent signalling pathways coupled to Ca 2+ i mobilization (Thomsen et al., 2012b (Thomsen et al., 2012b) . The observed differences in CaSR-mediated signalling and calcitonin release in response to Ca (Huang et al., 2009) as well as the HH domain (Ray and Northup, 2002; Mun et al., 2004) . In addition, a binding site for the tervalent cation Gd 3+ has been identified at the dimeric interface of neighbouring VFT domains in the crystal structure of the rat type-1 metabotropic glutamate receptor, a CaSR homologue (Tsuchiya et al., 2002) .
Thus, CaSR-acting drugs that selectively promote Gq/11-dependent activation of PI-PLC and ERK1/2 and, perhaps, promote the inhibition of cAMP formation (Chen et al., 1989) may suppress PTH secretion without disturbing calcitonin secretion. Since the development of cinacalcet and related calcimimetics, several classes of novel positive allosteric CaSR modulators have been identified (Harrington et al., 2010; Kiefer et al., 2010; Ma et al., 2011; Deprez et al., 2013) . Of these compounds, calcimimetic B (Amgen, Thousand Oaks, CA, USA), when compared with NPS R568, has reduced potency for the promotion of calcitonin release relative to its ability to inhibit PTH secretion in rats. In addition, in human TT medullary thyroid carcinoma C-cells, calcimimetic B exhibits reduced ability to stimulate calcitonin secretion when compared with the first generation phenylalkylamine, NPS R568 (Henley et al., 2011) . If these differences in selectivity are retained in vivo in treated patients, calcimimetic B or a related compound with reduced propensity to stimulate calcitonin release might reduce the frequency and/or severity of hypocalcaemic episodes.
Biased drugs that correct defective signalling engendered by naturally occurring mutations
Although CaSR mutations have traditionally been classified as 'loss-' or 'gain-of-function', their effects are not transmitted equally across all pathways. Some CaSR mutations differentially alter receptor signalling, resulting in a change in coupling preference (Leach et al., 2012 Leach et al., 2012) . In addition, we identified three naturally occurring mutations in which this coupling preference was lost, that is, both pathways were equally sensitive to Ca 2+ o (Leach et al., 2012) (Figure 3) . Thus, a drug that preferentially enhanced CaSR signalling via Ca 2+ i mobilization could be used to restore the natural signalling bias.
Type-II calcimimetics (positive modulators), including cinacalcet and NPS R568 (Nemeth et al., 1998) , and the calcilytic, NPS 2143 (Nemeth, 2002) , also engender biased signalling at the CaSR. These small-molecule drugs manifest greater allosteric modulation of Ca 2+ i mobilization relative to ERK1/2 phosphorylation and possess higher potency and estimated affinity for receptor states that mediate plasma membrane ruffling relative to either of the other two pathways investigated (Davey et al., 2012; Leach et al., 2013) . Thus, for mutants whose coupling to Ca 2+ i mobilization is compromised, cinacalcet corrects their signalling bias towards the coupling preference of the WT receptor.
Interestingly, some naturally occurring mutations of the CaSR alter the stimulus bias engendered by allosteric modulators. Positive allosteric modulation of the CaSR mutant R 680 C by cinacalcet, for example, is approximately equal in both Ca 2+ i mobilization and ERK1/2 phosphorylation assays. In the case of the CaSR mutant, V 817 I, however, cinacalcet exhibits a bias towards Ca 2+ i mobilization that is greater than that observed for the WT CaSR (Leach et al., 2013) .
Compared with WT, where NPS 2143 negatively modulates the potency of Ca However, in the case of V 836 L, little difference was observed between the modulation of either pathway (Leach et al., 2013) . These changes can be visualized on a 'bias plot' that depicts the relationship between changes in agonist potency in two dimensions (corresponding to two distinct receptordependent signalling pathways) in the presence of equimolar concentrations of modulator (Figure 4 ). For instance, the bias plots shown in Figure 4 depict the change in Ca i mobilization assays (y axis) and ERK1/2 phosphorylation assays (x axis). If the allosteric modulator exerts greater cooperativity on one pathway, the points fall on the corresponding side of the line of identity.
An understanding of how naturally occurring mutations alter the pharmacoregulation of the CaSR protein may permit predictions of the clinical responses to specific drug treatments in different tissues. Consistent with this idea, a small study in patients with secondary hyperparathyroidism in the context of end-stage renal failure reported that cinacalcet-mediated suppression of PTH was markedly enhanced in a patient homozygous for the polymorphism R 990 G (Rothe et al., 2005) .
Drugs that bias trafficking versus signalling
As noted earlier, various CaSR mutations reduce cell surface expression (Leach et al., 2012) , and the expression of some of these mutants is rescued by cinacalcet and related calcimimetics (White et al., 2009; Leach et al., 2013) . However, due to the positive modulation of CaSR signalling, CaSR activity is also significantly enhanced in response to calcimimetics and can readily exceed that of the WT CaSR ( Figure 5 ). Therefore, drug-induced increases in the cell surface expression and signalling of mutant receptors may drive a gain-of-function phenotype with enhanced sensitivity to Ca 2+ o and attendant hypocalcaemia. An ideal drug in this instance would positively modulate cell surface expression of the mutant receptor but have neutral cooperativity on signalling responses. The CaSR is localized to both the cell membrane and to intracellular compartments in recombinant and native CaSRexpressing cells (Rodriguez et al., 2005; Pidasheva et al., 2006; Bonomini et al., 2012) . CaSR agonists and positive allosteric modulators promote the forward trafficking and attendant
Figure 4
Allosteric stimulus bias is altered by naturally occurring CaSR mutations. Cooperativity bias plots highlight that allosteric compounds show bias in their modulation of Ca i mobilization and ERK1/2 phosphorylation assays was first fitted to an allosteric ternary complex model and 150 XY coordinates of points that defined the curve that best fit the equation were determined. Next, the XY coordinates for the two pathways were plotted against one another, with Ca 2+ i mobilization data on the y axis against ERK1/2 phosphorylation data on the x axis. These plots thus represent the change (Δ) in Ca 
Figure 5
Stimulus bias engendered by NPS 2143. Both cinacalcet and NPS 2143 modulate trafficking of loss-of-expression mutant CaSRs to the cell surface, but whereas cinacalcet is a positive modulator of CaSR signalling, NPS 2143 is a negative allosteric modulator of signalling. For mutants such as G 670 R, positive modulation of trafficking and signalling may lead to overstimulation of the receptor, whereas NPS 2143 may be more appropriate for balancing expression versus signalling. *Significantly different from value obtained in the absence of modulator (no modulator), one-way ANOVA.
glycosylation of intracellular receptors to the plasma membrane (McCormick et al., 2010; Grant et al., 2011) , a phenomenon that has been termed agonist-driven insertional signalling (ADIS). This is directly linked to membranelocalized receptor signalling events, as evidenced by attenuation of ADIS by inactivating CaSR mutations (Grant et al., 2011; . Strikingly, however, the small-molecule negative modulator (calcilytic) NPS 2143 also rescued cell surface expression of loss-of-expression mutants in HEK293 cells (Leach et al., 2013) . This is a remarkable example of biased allosteric modulation, with a complete reversal in cooperativity (positive vs. negative) between pathways (trafficking vs. acute signalling). Thus, NPS 2143 negatively modulates CaSRmediated signalling and positively modulates receptor trafficking to the cell surface.
The use of allosteric modulators of the CaSR that bias receptor trafficking to the exclusion of signalling may be extended to disease states in which aberrant CaSR expression contributes to the pathogenesis. Thus, up-regulated CaSR expression upon exposure to calcimimetics may provide an effective approach to the prevention and/or treatment of colon cancer.
However, positive modulation of CaSR signalling in other cell types in the gastrointestinal tract may induce unwanted side effects, for example, arising from enhanced release of gut hormones including gastrin and CCK (Buchan et al., 2001; Liou et al., 2011; Wang et al., 2011) . For example, oral administration of the calcimimetic KRN568 (NPS R568) caused gastrin release in human subjects (Igarashi et al., 2000) . Interestingly, Ca 2+ o-induced gastrin secretion from human G-cells occurs independently of cAMP inhibition, ERK1/2 or PLA2 signalling (Buchan et al., 2001) , so that a CaSR-acting agent that promotes CaSR trafficking and selectively modulates signalling towards ERK1/2 may be effective in the treatment of colon cancer and exhibit a favourable side effect profile. Alternatively, a positive modulator of trafficking with neutral effects on receptor signalling that possesses a rapid receptor off rate might be ideal for mediating the cell surface chaperoning effect while minimizing interference with receptor activation once at the plasma membrane.
Some proof of concept for targeting CaSR expression has been provided by treatment of nephrectomized rats (an animal model of secondary hyperparathyroidism) with the novel calcimimetic, AMG641, which up-regulates parathyroid CaSR protein and mRNA expression and inhibits parathyroid gland hyperplasia (Mendoza et al., 2009) . Furthermore, attenuation of CaSR expression has been linked to calcification of vascular smooth muscle cells (Alam et al., 2009) and expression is increased in the aortic intima of uraemic rats treated with the calcimimetic, NPS-R568. These rats show diminished calcification and reduced proliferation of vascular smooth muscle and endothelial cells in comparison with vehicle-treated controls (Koleganova et al., 2009) . These examples provide direct evidence that up-regulation of CaSR expression may be effective in treating certain disease states.
Summary
The CaSR is expressed widely in tissues throughout the body where it serves a multitude of functions through selective activation of distinct signalling pathways in response to diverse ligands. We now know that endogenous orthosteric and allosteric ligands as well as synthetic small-molecule allosteric drugs engender significant stimulus bias and provide the theoretical basis for the development of novel, highly selective therapeutics. Thus, drugs that activate a discrete 'signature' subset of receptor-mediated signalling pathways may be useful in the treatment of disorders such as osteoporosis, in which the selective recruitment and/or activation of osteoblasts would be beneficial. However, drugs that selectively promote receptor expression without disturbing the balance of downstream signalling pathways may be beneficial in disease states arising from defective CaSR expression (e.g. primary and secondary hyperparathyroidism, colon cancer and some forms of cardiovascular disease). Profiling of candidate calcimimetics, calcilytics and neutral modulators that up-or down-regulate CaSR expression across multiple signalling pathways will identify drugs that selectively promote CaSR trafficking and/or signalling and may provide new therapeutic options for various disorders.
